Molecular pathology and the art of drug design
6 August 2003 , By Dr Keith McCullagh , Summer 2003
Posted in Archive | Tagged AI / data analytics / healthtech / informatics, Analysis, Assay development optimisation & technology, Automation / robotics, Biochemistry, Biologics / Biotechnology, Business, Cell therapy, Chemical engineering, Chemistry, Clinical specialities, Clinical trials, Combinatorial chemistry, Drug development, Drug discovery, Drug targets, Gene therapy, Genetics / genomes, Genomics, High Throughput screening, Lead discovery, Medicinal chemistry, Metabolomics, Molecular medicine, Pathology, Pharmacology, Protein chemistry / Proteomics, Regulatory, RNA, Screening, Sequencing, Stem cells, System biology, Systems biology, Therapeutics, Toxicology, Virology / vaccines Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate of new drug approvals. Analysis [...]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
